Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Kura Oncology, Inc.
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
M.D. Anderson Cancer Center